+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID06612775

Randomized, Double-blind Study Evaluating Safety, Tolerability, and Efficacy of CB03-154 as Add-on Therapy in Adults With Focal Epilepsy

Led by Shanghai Zhimeng Biopharma, Inc. · Updated on 2026-09-22

180

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying CB03-154, an investigational drug developed by Shanghai Zhimeng Biopharma Inc., to evaluate its safety, tolerability, and effectiveness in reducing focal seizure frequency in adults with focal epilepsy who are taking 1 to 3 anti-epileptic drugs AEDs. This phase 2, randomized, double-blind, placebo-controlled trial also aims to assess the drugs impact on seizure severity and how it is processed by the body. Participants are randomly assigned to one of four groups three groups receive different doses of CB03-154 5mg, 10mg, or 20mg combined with placebo tablets or CB03-154 alone, and one group receives placebo tablets only. All doses are taken orally once daily for 12 weeks during the double-blind period. The study includes additional assessments to observe 50% response rates and trends in seizure frequency and severity. During the trial, participants will keep seizure diaries and undergo evaluations including plasma drug concentration measurements, depression rating scales, and global impression of change assessments. Safety is monitored by tracking adverse events throughout the 12-week treatment and a 2-week follow-up period. The total study duration covers up to 20 weeks, with participants closely observed to understand both efficacy and safety outcomes of CB03-154.

CONDITIONS

Brief Title

A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here